Jeyou Pharma has established a highly specialized commercialization team. Leveraging deep market insights, robust resources, and extensive industry experience, Jeyou Pharma remains committed to providing patients worldwide with medicines that offer unique clinical value and address unmet medical needs.
Jeyou Pharma has established a comprehensive and professional product marketing network in mainland China, providing high-value innovative medicines to patients through a variety of channels, thereby helping to enhance their medication experience and quality of life.
Jeyou Pharma is actively seeking overseas partnerships to contribute more Chinese innovation to global health. From November 2021 to December 2024, the company successfully licensed the overseas rights to four innovative drug intellectual property assets within three years: the KRAS inhibitor JMKX1899 was licensed to Shanghai Yaya Bio-Pharma International; the non-opioid analgesic JMKX000623 was licensed to the Finnish pharmaceutical company Orion; the oral AR degrader JMKX002992 was granted a global license to Genentech, a subsidiary of the multinational pharmaceutical company Roche; and the long-acting IgE antibody JYB1904 was licensed to RAPT.
Jeyou Pharma actively introduces internationally leading drugs into the Chinese market to meet the growing clinical needs in China. The innovative drug Oxido® (solidegib phosphate capsules), which has already been introduced, is China’s first basal cell carcinoma treatment. It is indicated for the treatment of adult patients with locally advanced basal cell carcinoma who are unsuitable for surgery or radiation therapy, or whose disease has recurred after surgery or radiation therapy, offering hope and a new treatment option to a wide range of basal cell carcinoma patients and their families.
